The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Official Title: A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111
Study ID: NCT00526799
Brief Summary: This multi-institutional phase I/II clinical trial will test the tolerability and efficacy of the combination sorafenib and topotecan in patients with recurrent ovarian cancer, which is platinum-resistant (recurrence within 6 months from completing platinum based therapy) or refractory (progressive disease during platinum based therapy).
Detailed Description: OUTLINE: This is a multi-center study. * Topotecan: 4mg/m2 weekly, 3 weeks on and one week off. * Sorafenib: Assigned cohort dose for phase I (up to 12 patients) Maximum tolerated dose for phase II (21 total patients) Cycles will consist of 4 weeks (28 days) with disease evaluations every 8 weeks. Non-PD and acceptable toxicity: Patients will continue protocol therapy PD or unacceptable toxicity: Patients will discontinue protocol therapy ECOG performance status 0-1 Life expectancy: Three (3) months Hematopoietic: * White blood cell count (WBC) \> 3 K/mm3 * Hemoglobin (Hgb) \> 9 g/dL * Platelets \> 100 K/mm3 * Absolute neutrophil count (ANC) \> 1.5 K/mm3 * INR \< 1.5 or a PTT within normal limits. NOTE: Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. * No evidence or history of bleeding diathesis or coagulopathy. Hepatic: * Bilirubin \< 1.5 x ULN * Aspartate aminotransferase (AST, SGOT) \< 2.5 x ULN * Alanine aminotransferase (ALT, SGPT) \< 2.5 x ULN * Alkaline phosphate \< 2.5 x ULN Renal: * Creatinine \< 1.5 x ULN Cardiovascular: * No history of myocardial infarction or angina pectoris or angina equivalent within 6 months prior to registration for protocol therapy (the patient may not be on anti-anginal or anti-arrhythmic medications), or have uncontrolled hypertension or congestive heart failure \> class II NYHA Pulmonary: * No thrombolic or embolic events such as a cerebrovascular accident, including transient ischemic attacks within the past 6 months. * No pulmonary hemorrhage/bleeding event \> CTCAE Grade 2 within 28 days prior to registration for protocol therapy. * No non-pulmonary hemorrhage/bleeding event \> CTCAE Grade 3 within 28 days prior to registration for protocol therapy.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
St. Vincent Hospital Cynecologic Oncology, Indianapolis, Indiana, United States
Arnett Cancer Care, Lafayette, Indiana, United States
Medical Consultants, P.C., Muncie, Indiana, United States
Schwartz Gynecologic Oncology, PLLC, Brightwaters, New York, United States
Name: Daniela Matei, M.D.
Affiliation: Hoosier Oncology Group, Inc.
Role: STUDY_CHAIR